SCHEMBL2069906

SCHEMBL2069906

O=C(O)COc1ccc(SCc2cc(C#Cc3ccc(C(F)(F)F)cc3)nc(C#Cc3ccc(C(F)(F)F)cc3)c2)c2c1CCC2

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 20/20 0.67
PPARA Q07869 14/20 0.67
PPARG P37231 8/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12646865 0.94 PPARD (0.61) PPARDPPARAPPARG
SCHEMBL2826247 0.82 PPARD (0.43) PPARDPPARAPPARG
SCHEMBL2068046 0.82 PPARD (0.68) PPARDPPARAPPARG
SCHEMBL5509858 0.81 PPARD (0.82) PPARDPPARAPPARG
SCHEMBL5510532 0.81 PPARD (0.82) PPARDPPARAPPARG
SCHEMBL5513213 0.80 PPARD (1.00) PPARDPPARAPPARG
SCHEMBL5509985 0.79 PPARD (0.68) PPARDPPARAPPARG
SCHEMBL2068248 0.79 PPARD (0.63) PPARDPPARAPPARG
SCHEMBL5512600 0.78 PPARD (0.76) PPARDPPARAPPARG
SCHEMBL2069300 0.78 PPARD (0.64) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968723-B2 Compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2011-06-28 US claimed
EP-1745003-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-10-27 EP claimed
US-20090209588-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2009-08-20 US claimed
EP-1745003-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 EP claimed
WO-2005105726-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-7968723-B2 Compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2011-06-28 US disclosed
US-7968723-B2 Compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2011-06-28 US disclosed
EP-1745003-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-10-27 EP disclosed
US-20090209588-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2009-08-20 US disclosed
US-20090209588-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2009-08-20 US disclosed
EP-1745003-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 EP disclosed
WO-2005105726-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209588-A1 Novel compounds, their preparation and use PPARG, PPARD, GPR119 PPARD 2/4885PPARA 4/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.